Limited conclusions can be drawn on the observed numerical differences in DoR and PFS between the two datasets, which may be due to differences between the trial populations, such as using liquid biopsies for patient selection that required detectable ctDNA at baseline, which has been shown to be positively correlated with higher tumor burden11,31,32, or other potentially prognostic factors, such as the prevalence of TP53 comutations11,33,34. The gene discussed is TP53; the disease is neoplasm.